Radioimmunotherapy of Prostate Cancer in Human Xenografts Using Monoclonal Antibodies Specific to Prostate Specific Membrane Antigen (PSMA): Studies in Nude Mice

Prostate

Volumn 58, Issue 2, 2004, Pages 145-155

  Vallabhajosula, Shankar ^a,b   Smith Jones, Peter M ^a   Navarro, Vincent ^a   Goldsmith, Stanley J ^a   Bander, Neil H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Division of Nuclear Medicine   (United States)

Author keywords

131I huJ591 MAb; 90Y huJ591 MAb; Anti PSMA antibody; LNCaP xenografts; Prostate specific membrane antigen (PSMA)

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; EPITOPE; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUJ591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG SPECIFICITY; HUMAN; HUMAN CELL; MALE; MAXIMUM TOLERATED DOSE; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CHELATING AGENTS; GLUTAMATE CARBOXYPEPTIDASE II; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IODINE RADIOISOTOPES; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RANDOM ALLOCATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 0742287749     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10281     Document Type: Article

References (46)

1. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25:1341-1351.
2. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902-1909.
3. Mariani G, Bodei L, Adelstein SJ, Kassis AI. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. J Nucl Med 2000;41:1519-1521.
4. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-Lopez A, Chinn P, Varns C, Ning NC, Fowler S, Deb N, Becker M, Marquez C, Levy R. Yttrium-90 labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell Lymphoma. Clin Cancer Res 1996;2:457-470.
5. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-1266.
6. Chang SS, Bander NH, Heston WD. Monoclonal antibodies: Will they become an integral part of the evaluation and treatment of prostate cancer-Focus on prostate-specific membrane antigen? Curr Opin Urol 1999;9:391-395.
7. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-1811.
8. Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998;4:295-302.
9. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 1990;50:6423-6429.
10. Wright GL Jr., Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18-28.
11. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-558.
12. Wright GL Jr., Grob M, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Up-regulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-334.
13. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
14. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-936.
15. Israeli RS, Powell CT, Fair WR, Heston WDW. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-230.
16. Rinker-Schaeffer CW, Hawkins AL, Su SL, Israeli RS, Griffin CA, Isaacs JT, Heston WDW. Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics 1995;30:105-108.
17. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. Cancer 1998;82:2256-2261.
18. 111Indium-labeled monoclonal antibody CYT-356. J Urol 1994;152:1952-1955.
19. 111Indium-labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490-1495.
20. Troyer JK, Feng Q, Beckett ML, Wright GL Jr. Biochemical characterization and mapping of the 7E11=C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1995;1:29-37.
21. Troyer JK, Beckett ML, Wright L Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997;30:232-242.
22. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor endothelium. Cancer Res 1997;57:3629-3634.
23. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58:4055-4060.
24. Holmes EH. PSMA specific antibodies and their diagnostic and therapeutic use. Exp Opin Invest Drugs 2001;10:511-519.
25. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer Res 2000;60:5237-5243.
26. ext): Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44:610-617.
27. Deshpande SV, DeNardo SJ, Kukis DL, Moi MK, McCall MJ, DeNardo GL, Meares CF. Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990;3:473-479.
28. 131I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med 2001;42:1251-1256.
29. Loevinger R, Berman M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD pamphlet No. 1, revised. New York: Society of Nuclear Medicine, 1976.
30. 90Y-labeled 1B4M-DTPA antitac monoclonal antibody distribution. J Nucl Med 1999;40:268-276.
31. 111In radiometals. J Nucl Med 2001;42:1281-1287.
32. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 1994;35:152-156.
33. 131I. J Nucl Med 2001;42:967-974.
34. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 1993;34:689-694.
35. Muthuswamy MS, Roberson PL, Buchsbaum DJ. A mouse bone marrow dosimetry model. J Nucl Med 1993;39:689-694.
36. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL. Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci 1997;94:4000-4004.
37. DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med 1998;39:842-849.
38. 90Y-DOTA-peptide-ChL6 for PC3-tumored mice. Prostate 2000;44:187-192.
39. Stein R, Chen S, Maim S, Goldenberg DM. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer 1997;80:2636s-2641s.
40. Behr TM, Sgouros G, Stabin MG, Behe M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W. Studies on the red marrow dosimetry in radioimmunotherapy: An experimental investigation of the factors influencing the radiation-induced myelotoxicity in therapy with β-,auger/conversion electron- or α-emitters. Clin Cancer Res 1999;5:3031s-3043s.
41. 131I radioimmunotherapy and fractionated external beam radiotherapy: Comparative effectiveness in a human tumor xenograft. J Nucl Med 1999;40:1764-1768.
42. 90Y-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1988;48:3270-3275.
43. Schmidberger H, Buchsbaun DJ, Blazar BR, Everson P, Vallera DA. Radiotherapy in mice with yttrium-90 labeled anti-Ly 1 monoclonal antibody: Therapy of the T cell lymphoma EL4. Cancer Res 1991;51:1883-1890.
44. O' Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902-1909.
45. Hui TE, Fisher DR, Kuhn JA, Williams LE, Novrigat C, Badger CC, Beatty BG, Beatty JD. A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer 1994;73:951-957.
46. O' Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 1999;40:1337-1341.